Latest Breaking News On - Immunology innovation program - Page 8 : comparemela.com

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia - argenx (NASDAQ:ARGX)

Study did not meet primary or secondary endpointsFavorable safety and tolerability profile consistent with previous clinical trials Conference call scheduled for today, November 28, 2023 at 8:30am ET (2:30pm CET)

United statesNoord hollandUnited kingdomBen petokLuc truyenExchange commissionImmunology innovation programInternational working groupChief medical officerImmune thrombocytopeniaAbuse regulation

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNoord hollandAnant murthyBen petokEuropean unionEuropean union eu member statesImmunology innovation programExchange commissionEuropean commissionCommittee for medicinal products human useMember statesGeneral managerMedicinal productsHuman useNorth america

argenx SE: argenx Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

argenx SE: argenx Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Noord hollandRheinland pfalzUnited statesUnited kingdomBen petokAnant murthyImmunology innovation programEuropean union eu member statesEuropean commissionExchange commissionCommittee for medicinal products human useEuropean unionMember statesGeneral managerMedicinal productsHuman use

argenx Announces European Commission Approval of

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration.

Noord hollandUnited kingdomUnited statesBen petokAnant murthyImmunology innovation programEuropean union eu member statesEuropean commissionCommittee for medicinal products human useMember statesGeneral managerMedicinal productsHuman useNorth americaBrussels stock exchange argxArgenx se

argenx SE: argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

argenx SE: argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNoord hollandMjamesf howardGil wolfeDemyelinating polyneuropathyYuebing liA gordon smithPushpa narayanaswamiGlenn phillipsCynthia qiLuc truyenTom hughesBen petokJamesf howard jrAntoine azar